Why the study?
Does routine surveillance endomyocardial biopsy after 12 months post-heart transplantation improve cost-effectiveness compared to stopping routine biopsy at 12 months?
Population
Heart transplant patients entering the model at 12 months post-transplant
Comparison
Routine surveillance endomyocardial biopsy… vs Stopping routine surveillance EMB at 12 months…
Follow-up
until 36 months post-transplant
Authors
Loading...
May support stopping routine EMB at 12 months to reduce costs without losing effectiveness; leaves open need for prospective validation.
Does routine surveillance endomyocardial biopsy after 12 months post-heart transplantation improve cost-effectiveness compared to stopping routine biopsy at 12 months?
Stopping routine surveillance endomyocardial biopsy at 12 months post-heart transplant is more effective and less costly than continuing surveillance biopsies, supporting a shift away from prolonged routine surveillance.
Lampert et al. (2014) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: